253 related articles for article (PubMed ID: 29091534)
1. American Society of Clinical Oncology Position Statement on Addressing the Affordability of Cancer Drugs.
American Society of Clinical Oncology
J Oncol Pract; 2018 Mar; 14(3):187-192. PubMed ID: 29091534
[No Abstract] [Full Text] [Related]
2. Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
Bennett CL; Sartor OA; Armitage JO; Kantarjian H
Lancet Oncol; 2017 Jan; 18(1):22-23. PubMed ID: 28049571
[No Abstract] [Full Text] [Related]
3. How do biosimilars sustain value, affordability, and access to oncology care?
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):327-329. PubMed ID: 32842809
[No Abstract] [Full Text] [Related]
4. Introduction and commentary: Paving the way for biosimilars in oncology.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S1-4. PubMed ID: 24267943
[No Abstract] [Full Text] [Related]
5. Economic perspective of cancer treatment in India.
Natarajan A; Mehra N; Rajkumar T
Med Oncol; 2020 Oct; 37(11):101. PubMed ID: 33057841
[TBL] [Abstract][Full Text] [Related]
6. Affordability of Cancer Drugs in Sub-Saharan Africa: Effects of Pricing on Needless Loss of Life.
Martei YM; Binagwaho A; Shulman LN
JAMA Oncol; 2017 Oct; 3(10):1301-1302. PubMed ID: 28426846
[No Abstract] [Full Text] [Related]
7. Emerging Opportunities and Challenges of Biosimilars in Oncology Practice.
Lyman GH
J Oncol Pract; 2017 Sep; 13(9_suppl):7s-9s. PubMed ID: 28898591
[No Abstract] [Full Text] [Related]
8. Biosimilars in Oncology: Reality Could Bite the Copycats, Dog Potential Major Savings.
Kelley T
Manag Care; 2017 Mar; 26(3):28-30. PubMed ID: 28510517
[TBL] [Abstract][Full Text] [Related]
9. The shortage of essential chemotherapy drugs in the United States.
Gatesman ML; Smith TJ
N Engl J Med; 2011 Nov; 365(18):1653-5. PubMed ID: 22040130
[No Abstract] [Full Text] [Related]
10. Journey of Generic Imatinib: A Case Study in Oncology Drug Pricing.
Chen CT; Kesselheim AS
J Oncol Pract; 2017 Jun; 13(6):352-355. PubMed ID: 28445102
[No Abstract] [Full Text] [Related]
11. Empower physicians to fight financial toxicity with biosimilars.
Oubre K
Am J Manag Care; 2019 Dec; 25(12 Spec No.):SP374-SP375. PubMed ID: 31860250
[No Abstract] [Full Text] [Related]
12. A Conversation with Gary Lyman, MD: Biosimilars and the Search for the Cure To Cancer Treatment's Financial Toxicity.
Wehrwein P
Manag Care; 2019 Jan; 28(1):12-15. PubMed ID: 30883317
[TBL] [Abstract][Full Text] [Related]
13. Repurposing Drugs in Oncology: Next Steps.
Verbaanderd C; Meheus L; Huys I; Pantziarka P
Trends Cancer; 2017 Aug; 3(8):543-546. PubMed ID: 28780930
[TBL] [Abstract][Full Text] [Related]
14. Generics and Biosimilars: Barriers and Opportunities.
Scheckel CJ; Rajkumar SV
Mayo Clin Proc; 2021 Dec; 96(12):2947-2957. PubMed ID: 34728057
[No Abstract] [Full Text] [Related]
15. Prescription drug prices in the US.
Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
[No Abstract] [Full Text] [Related]
16. Tackling Cost: A Prescription for Spending Wisely.
Tempero M
J Natl Compr Canc Netw; 2019 Jun; 17(6):633. PubMed ID: 31200360
[No Abstract] [Full Text] [Related]
17. Biosimilars and drug development in allergic and immunologic diseases.
Bonini S; Bonini M
J Allergy Clin Immunol; 2017 May; 139(5):1461-1464. PubMed ID: 28359671
[No Abstract] [Full Text] [Related]
18. Developing oncology biosimilars: an essential approach for the future.
Abraham J
Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
[TBL] [Abstract][Full Text] [Related]
19. The role of generic medicines and biosimilars in oncology in low-income countries.
Renner L; Nkansah FA; Dodoo AN
Ann Oncol; 2013 Sep; 24 Suppl 5():v29-32. PubMed ID: 23975702
[TBL] [Abstract][Full Text] [Related]
20. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
Tu SS; Sarpatwari A
N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
[No Abstract] [Full Text] [Related]
[Next] [New Search]